65 results about "Granzyme B" patented technology

T cell immune responses are enhanced by presentation of antigen to CD8⁺ T cells using a chimeric nucleic acid immunogen or vaccine that links DNA encoding an antigen with DNA encoding a polypeptide that targets or translocates the antigenic polypeptide to which it is fused (immunogenicity-potentiating polypeptides or “IPP”). By inhibiting apoptosis in the vicinity of a T cell responses to such a nucleic acid immunogen, even more potent immune responses are attained. The present strategy prolongs the survival of DNA-transduced cells, including dendritic cells (DCs), thereby enhancing the priming of antigen-specific T cells and increase potency. Co-delivery of DNA encoding an inhibitor of apoptosis, including (a) BCL-xL, (b) BCL-2, (c) XIAP, (d) dominant negative caspase-9, or (e) dominant negative caspase-8, or (f) serine protease inhibitor 6 (SPI-6) which inhibits granzyme B, with DNA encoding an antigen, prolongs the survival of transduced DCs and results in significant enhancement of antigenspecific T cell immune responses that provide potent antitumor effects. Thus, co-administration of a DNA vaccine encoding antigen linked to an IPP along with one or more DNA constructs encoding an anti-apoptotic protein provides a novel way to enhance vaccine potency.

The 121-amino acid isoform of vascular endothelial growth factor (VEGF₁₂₁) is linked by a flexible G4S tether to a cytotoxic molecule such as toxin gelonin or granzyme B and expressed as a soluble fusion protein. The VEGF₁₂, fusion protein exhibits significant anti-tumor vascular-ablative effects that inhibit the growth of primary tumors and inhibit metastatic spread and vascularization of metastases. The VEGF₁₂₁ fusion protein also target osteoclast precursor cells in vivo and inhibits osteoclastogenesis.

Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.

The present invention relates to a method for diagnosis, detection, or prognosis of sepsis and its severity. More specifically, this invention uses the presence and amount of granzyme B in platelets as a marker for sepsis.

Pyrrole compounds as Granzyme B inhibitors, compositions that include the compounds, and methods for using the compounds. Method for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided.

Methods of promoting wound healing in a subject is disclosed. The method include applying a Granzyme B (Granzyme B) inhibitor to the wound. The wound may be a skin wound. The Granzyme B inhibitor may be comprised of nucleic acids, or peptides, including but not limited to antibodies, or small molecules.

Granzyme B inhibitor compounds, compositions that include the compounds, and methods for using the compounds. The compounds of the invention have advantageous water solubility and effectively inhibit Granzyme B.

An ultraviolet (UV) disinfection unit for disinfecting catheter line connections is provided. The unit can be used to disinfect solution set and transfer set catheters used for peritoneal dialysis. The unit can comprise a concavely curved bottom surface. A tubing trough of the unit can allow for ambidextrous positioning.

A method for the preparation of a polypeptide of interest in authentic form by enzymatic cleavage of fusion proteins using Granzyme B protease (EC 3.4.21.79). There is also provided fusion proteins comprising a polypeptide of interest and a fusion partner, wherein the junction region between the polypeptide of interest and the fusion partner comprises a Granzyme B protease cleavage site adjacent to the polypeptide of interest, and a human Granzyme B protease variant wherein the Cystein residue no. 228 (chymotrypsinogen numbering) is mutated to Phenylalanine.

A fusion protein including granzyme B, a cell penetrating peptide, a cleavage site, and a targeting moiety, a composition for cell membrane penetration comprising the fusion protein, and an anticancer composition comprising the fusion protein.

The invention provides a sequence for expressing targeted double-recombinant apoptosis proteins of liver cancer, which is a DNA sequence for regulating the expression of two apoptosis proteins of Caspase 3 and Granzyme B by using a specific AFP promoter, and has a nucleotide sequence shown as SEQID No:1. The sequence utilizes the function of targeted regulation of an AFP enhancer/promoter transcriptional regulatory element to lead foreign gene to be expressed in liver cancer cells with positive AFP, thus realizing targeted and high-efficiency anti-tumor effect; and the sequence constructs recombinant activated type Caspase-3 molecule, applies the recombinant activated type Caspase-3 to pro-apoptotic effect for target cells, introduces granzyme B, fuses the granzyme B and the recombinant activated type Caspase-3 molecule, and mediates the apoptosis of the target cells. The invention also provides an application in preparing targeted gene drugs for treating the liver caner with the positive AFP.

The invention discloses an application of quercitrin in preparation of a human gamma delta T cell proliferator, and relates to the technical field of medicines. Quercitrin can remarkably promote proliferation of human gamma delta T cells and promote expression of perforin and granzyme B, so that the quercitrin is of certain dose dependency. The gamma delta T cell treated by the quercitrin can promote expression of p-ERK (Extracellular signal-Regulated Kinase)1/2 and p-Akt in active form and promote expression of an anti-apoptoasis protein Bcl-2, so that the gamma delta T cell is of certain dose dependency. The invention discovers the novel medical use of quercitrin and provides experimental references to development of tumor immunotherapy medicines.

The invention belongs to the technical field of biology, and discloses an application of a myeloid cell triggering receptor 2 as a novel coronavirus pneumonia diagnosis or treatment target. Through research, TREM-2 is found to be highly expressed in CD4+ and CD8+T cells of peripheral blood of a patient suffering from novel coronavirus pneumonia and is positively correlated with the severity of a disease. The TREM-2 can be used as a marker for novel coronavirus pneumonia diagnosis and prognosis, and a TREM-2-Fc fusion protein (with an action effect of blocking TREM-2 signals) obviously reducesthe levels of cytokines IFN-g, TNF, IL-2 and Granzyme B. TREM-2 expression has significant correlation with severe indexes of aging, lymphocyte count reduction, C-reactive protein and D-dimer increaseproposed by a''novel coronavirus pneumonia diagnosis and treatment scheme''. Intervention of expression of TREM-2 is prompted to be capable of relieving or even be expected to treat novel coronaviruspneumonia.

A novel cell type has been generated that has both Thl characteristics and cytolytic activity. These Thl/killer cells are CD4+ cells purified from peripheral blood and manipulated to have Thl characteristics such as production of IFN-gamma combined with cytolytic activity similar to cytotoxic T-cells (CTL). The CTL activity is targeted toward diseased cells, not normal cells. The cytolytic activity of the Thl/killer cells is mediated by Granzyme B-Perforin mechanism and results in apoptotic death of diseased cells. Methods of producing and using these Thl/killer cells include isolating CD4+ cells from peripheral blood, activating the CD4+ T- cells to form Thl/killer cells and administering these Thl/killer cells with the cytolytic activity to a patient wherein theThl/killer cells are allogeneic to the patient.

Azaindoline compounds as granzyme B inhibitors, compositions that include the compounds, and methods for using the compounds. Methods for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided.

The present invention relates to a modified polypeptide with a biological activity to lyse cell walls of bacteria, wherein the polypeptide has no caspase, clostripain, enterokinase, factor Xa, granzyme B, staphylococcus peptidase I (V8 Protease), plasmin, streptopain, bacillolysin and/or thrombin cleavage site. The invention further relates to nucleic acids with a sequence encoding a polypeptide according to the present invention.